• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

    2/24/26 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care
    Get the next $RMD alert in real time by email

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed's U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America.

    The Greenwood center will operate as a major logistics hub, enhancing the delivery of essential healthcare products across North America while reinforcing Resmed's commitment to the local Greenwood community. It's estimated that the facility will employ more than 100 full-time and contingent workers over time across operations, logistics and management. Resmed is working closely with local and state partners, including the State of Indiana and the City of Greenwood, to support job creation and advance the project.

    The Greenwood center complements Resmed's existing distribution centers in Atlanta, Georgia and Moreno Valley, California. Its central location will connect coastal operations and support ongoing improvements in efficiency, productivity and delivery speed. Once fully operational, it will improve two-day transit coverage across North America from 75% to 90% and shorten delivery times to Canada by one full day.

    "We're proud to grow our U.S. footprint and invest in the local Greenwood community," said Shane Azzi, chief supply chain officer at Resmed. "Greenwood's talented workforce and strong spirit of collaboration played a major role in our decision to locate here. The new distribution center will help us deliver products more quickly, strengthen our ability to serve patients and providers and support the region's long term growth."

    "Indiana's life sciences sector continues to attract new global and innovative leaders to the state," said Indiana Governor Mike Braun. "Here in the crossroads of the U.S., Resmed will be centrally located and have access to robust infrastructure, helping the company serve customers more quickly and deliver life-changing solutions."

    "Resmed's decision to locate in Greenwood is a win for our residents and our local economy," said Mark W. Myers, Mayor of Greenwood. "This investment reflects our pride in bringing high-quality jobs to Greenwood and expanding the region's role in delivering essential healthcare products nationwide. We're grateful that Resmed chose Greenwood as the home for this new operation."

    About Resmed

    Resmed (NYSE:RMD, ASX: RMD)) creates life-changing health technologies that people love. We're relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we're redefining sleep health at Resmed.com and follow @Resmed.

    For MediaFor Investors
    Caela ShaySalli Schwartz
    [email protected][email protected] 
    [email protected][email protected]





    Primary Logo

    Get the next $RMD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RMD

    DatePrice TargetRatingAnalyst
    12/16/2025$275.00Outperform → Neutral
    Robert W. Baird
    9/18/2025$330.00Buy
    Citigroup
    9/2/2025Hold → Outperform
    CLSA
    7/16/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    7/15/2025$294.00Sector Perform → Outperform
    RBC Capital Mkts
    3/19/2025$280.00Overweight
    Morgan Stanley
    3/19/2025Overweight
    Morgan Stanley
    1/16/2025Buy
    Goldman
    More analyst ratings

    $RMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ResMed downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded ResMed from Outperform to Neutral and set a new price target of $275.00

    12/16/25 8:57:57 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Citigroup initiated coverage on ResMed with a new price target

    Citigroup initiated coverage of ResMed with a rating of Buy and set a new price target of $330.00

    9/18/25 8:44:39 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed upgraded by CLSA

    CLSA upgraded ResMed from Hold to Outperform

    9/2/25 11:05:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Resmed Expands U.S. Operations with New Distribution Center in Greenwood, Indiana

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)), the leading health technology company focused on sleep, breathing and care delivered in the home, is opening a new distribution center in Greenwood, Indiana. Scheduled to begin operations in 2027, the center will expand Resmed's U.S. presence and strengthen the company's distribution capacity to better serve patients and providers across North America. The Greenwood center will operate as a major logistics hub, enhancing the delivery of essential healthcare products across North America while reinforcing Resmed's commitment to the local Greenwood community. It's estimated that the facility will employ more than 100

    2/24/26 9:00:00 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2025. "Our second quarter results demonstrate the strength and resilience of our global business a

    1/29/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

    SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:https://investor.resmed.com•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST / 4:30 p.m. EST•International:London, Thursday, January 29, 2026, 9:30 p.m. GMT  Sydney, Friday, January 30, 2026, 8:30 a.m. AEDT Please note, Resmed

    1/8/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman and CEO Farrell Michael J. exercised 4,991 units of ResMed Common Stock at a strike of $146.34 and sold $1,366,436 worth of ResMed Common Stock (4,991 units at $273.78) (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/10/26 1:33:22 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Director Farrell Peter C sold $502,620 worth of ResMed Common Stock (2,000 units at $251.31), decreasing direct ownership by 3% to 64,773 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/6/26 11:07:47 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Global General Counsel Rider Michael J sold $13,000 worth of ResMed Common Stock (50 units at $260.00), decreasing direct ownership by 0.51% to 9,691 units (SEC Form 4)

    4 - RESMED INC (0000943819) (Issuer)

    2/6/26 11:05:33 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    SEC Filings

    View All

    SEC Form 10-Q filed by ResMed Inc.

    10-Q - RESMED INC (0000943819) (Filer)

    1/29/26 7:37:18 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    ResMed Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - RESMED INC (0000943819) (Filer)

    1/29/26 4:05:45 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by ResMed Inc.

    S-8 - RESMED INC (0000943819) (Filer)

    11/21/25 1:17:30 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Financials

    Live finance-specific insights

    View All

    Resmed Inc. Announces Results for the Second Quarter of Fiscal Year 2026

    Revenue increased by 11% to $1.4 billion; up 9% on a constant currency basis Gross margin up 320 bps to 61.8%; non-GAAP gross margin up 310 bps to 62.3%Income from operations increased 18%; non-GAAP income from operations up 19%Diluted earnings per share of $2.68; non-GAAP diluted earnings per share of $2.81Operating cash flow of $340 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended December 31, 2025. "Our second quarter results demonstrate the strength and resilience of our global business a

    1/29/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed to Report Second Quarter Fiscal 2026 Earnings on January 29, 2026

    SAN DIEGO, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD)) today announced it plans to release financial and operational results for the second quarter of fiscal year 2026 on Thursday, January 29, 2026, after the New York Stock Exchange closes. Following the release, Resmed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details:•Location:https://investor.resmed.com•Date:Thursday, January 29, 2026•Time:1:30 p.m. PST / 4:30 p.m. EST•International:London, Thursday, January 29, 2026, 9:30 p.m. GMT  Sydney, Friday, January 30, 2026, 8:30 a.m. AEDT Please note, Resmed

    1/8/26 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026

    Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0%Income from operations increased 15%; non-GAAP income from operations up 19%Diluted earnings per share of $2.37; non-GAAP diluted earnings per share of $2.55Operating cash flow of $457 million Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE:RMD, ASX: RMD)) today announced results for its quarter ended September 30, 2025. "Our fiscal year 2026 is off to a strong start, with first-quarter performance r

    10/30/25 4:05:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/23 1:36:52 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 5:05:17 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by ResMed Inc. (Amendment)

    SC 13G/A - RESMED INC (0000943819) (Subject)

    2/10/22 8:32:59 AM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    $RMD
    Leadership Updates

    Live Leadership Updates

    View All

    Resmed Names Salli Schwartz as Chief Investor Relations Officer

    SAN DIEGO, April 21, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE:RMD, ASX: RMD), ASX: RMD), the global leader in health technology focused on sleep, breathing, and care delivered in the home, today announced the appointment of Salli Schwartz as Chief Investor Relations Officer, effective April 21, 2025. In this role, Schwartz will lead Resmed's global investor relations function and report to Mick Farrell, Chairman of the Board and CEO. Schwartz is a seasoned executive with more than two decades of experience in a range of finance roles at health tech and financial services organizations. She joins Resmed from Illumina, Inc., where she served as the Head of Investor Relations. In that role, she

    4/21/25 5:00:00 PM ET
    $RMD
    Medical/Dental Instruments
    Health Care

    Jan De Witte joins GHO Capital as Operating Partner

    Jan De Witte joins GHO Capital as Operating Partner Former CEO of Integra LifeSciences with significant strategic and operational experience to support GHO Capital's portfolio London, UK – 11 February 2025: Global Healthcare Opportunities, or GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, is pleased to announce the appointment of Jan De Witte as Operating Partner. Jan is an accomplished senior executive with extensive experience leading international growth and transformation for global technology and life sciences companies. Prior to joining GHO, he was Chief Executive Officer and member of the Board of Directors at Integra LifeSciences (("Integr

    2/11/25 4:30:00 AM ET
    $IART
    $RMD
    Medical/Dental Instruments
    Health Care

    Incannex Healthcare Appoints Alison Wimms, Ph.D. to Newly Formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board

    NEW YORK and MELBOURNE, Australia, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), (Incannex), a clinical-stage biopharmaceutical company leading the way in developing combination medicines today announced the appointment of Alison Wimms, Ph.D. as an advisor to its newly formed IHL-42X Obstructive Sleep Apnea (OSA) Clinical Advisory Board where she will represent ResMed. Dr. Wimms brings two decades of sleep medicine industry and research expertise to her advisory role at Incannex. Dr. Wimms holds a Doctor of Philosophy (Ph.D.) in Medicine, and Master of Medicine (Sleep Medicine) and Bachelor of Science degrees from the University of Sydney. "Incannex's

    2/4/25 9:15:00 AM ET
    $IXHL
    $RMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments